GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,342.00GBp
21 Oct 2014
Price Change (% chg)

3.00p (+0.22%)
Prev Close
1,339.00p
Open
1,336.00p
Day's High
1,342.00p
Day's Low
1,324.00p
Volume
12,689,281
Avg. Vol
9,657,763
52-wk High
1,709.00p
52-wk Low
1,296.50p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.50
Market Cap (Mil.): £68,648.47
Shares Outstanding (Mil.): 4,849.77
Dividend: 19.00
Yield (%): 5.65

Financials

  GSK.L Industry Sector
P/E (TTM): 16.50 33.21 34.06
EPS (TTM): 0.86 -- --
ROI: 16.65 18.18 17.45
ROE: 75.96 18.85 18.26
Search Stocks

Exclusive: Advent, Avista near deal for UCB's Kremers Urban - sources

- A consortium of buyout firms Advent International Corp and Avista Capital Partners is in advanced talks to acquire UCB SA's U.S. generic drugs unit Kremers Urban Pharmaceuticals Inc, according to people familiar with the matter.

22 Oct 2014

UPDATE 6-Drugmakers to join forces to make millions of Ebola vaccine doses

* GlaxoSmithKline sees first vaccine doses ready this year

22 Oct 2014

GSK eyes prime FTSE 100 slot for standalone HIV drugs business

LONDON - GlaxoSmithKline , battered by weak U.S. drug sales and a bribery scandal in China, is looking to float its fast-growing HIV drugs business as part of a recovery plan that includes a fresh round of cost cutting. | Video

22 Oct 2014

Motor insurers help Britain's FTSE to end higher

LONDON, Oct 22 - Britain's top share index ended higher on Wednesday, with motor insurers advancing on news of an increase in car premiums and drugmaker GlaxoSmithKline rising after its results.

22 Oct 2014

Motor insurers help Britain's FTSE to end higher

LONDON, Oct 22 - Britain's top share index ended higher on Wednesday, with motor insurers advancing on news of an increase in car premiums and drugmaker GlaxoSmithKline rising after its results.

22 Oct 2014

UPDATE 2-GSK eyes prime FTSE 100 slot for standalone HIV drugs business

* Company going through "painful" period as Advair slides

22 Oct 2014

Motor insurers help Britain's FTSE edge higher

LONDON, Oct 22 - Britain's top share index edged higher late on Wednesday, with motor insurers advancing on news of a rise in car premiums and drugmaker GlaxoSmithKline gaining after its results.

22 Oct 2014

GSK sees first Ebola vaccine doses ready late this year

LONDON - GlaxoSmithKline expects to have the first doses of its Ebola vaccine ready late this year and is looking to work with the rest of the pharmaceutical industry to scale up production.

22 Oct 2014

GSK sees first Ebola vaccine doses ready late this year

LONDON, Oct 22 - GlaxoSmithKline expects to have the first doses of its Ebola vaccine ready late this year and is looking to work with the rest of the pharmaceutical industry to scale up production.

22 Oct 2014

GlaxoSmithKline holds dividend, eyes IPO of HIV unit

LONDON, Oct 22 - GlaxoSmithKline kept its dividend unchanged for the third quarter, breaking a run of steadily rising payouts, as U.S. pricing pressure on its top-selling lung drug Advair eroded sales and profit.

22 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Jefferson Research
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks